Stockreport

Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution [Seeking Alpha]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF OLMA is advancing palazestrant in late-stage trials for ER+/HER2- breast cancer, targeting both first-line and later-line settings, with pivotal readouts expected in 20 [Read more]